Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom.
Loading...
LTHT Author
LTHT Department
Contributor Profession (Non Medical)
Publication Date
Item Type
Journal Article
Language
Subject
HAEMATOLOGIC NEOPLASMS
Subject Headings
Journal Title
Journal ISSN
Volume Title
Abstract
Trametinib (MEK inhibitor) shows efficacy in refractory and high-risk adult histiocytic neoplasms. At a median follow-up of 21.4 months, the clinical response rate was 81% (30/37) and the radiological response was 68% (25/37) (n = 37).
Journal
British Journal of Haematology